Low AMH, ovarian reserve, and planning IVF
AMH is a blood test that provides an indication of the pool of follicles with the potential to develop in the ovaries. A low result generally suggests that the ovarian response to stimulation medication may be limited; however, it does not independently indicate egg genetic quality, the likelihood of natural conception, or the outcome of IVF.
Age, antral follicle count, menstrual regularity, previous ovarian response, semen analysis, and assessment of the uterus are evaluated together. Therefore, it is not medically accurate to conclude “there is no chance” or “success is guaranteed” based solely on an AMH result.
In Turkey, the initial assessment generally includes consultation with an obstetrician-gynecologist and fertility specialist, antral follicle counting by ultrasound during the menstrual cycle, hormone tests, and, when considered necessary, evaluation of the uterus and fallopian tubes. The treatment plan aims to assess the available ovarian reserve as realistically as possible.
Evidence regarding PRP and stem cell applications for low AMH
The current position of the PRP approach
Ovarian PRP refers to the application of platelet-rich plasma prepared from the patient's own blood to ovarian tissue. The approach is based on the assumption that it may improve ovarian function or follicular response; however, current clinical studies have not conclusively shown that it increases egg number, egg quality, or live birth rates.
Some studies have small sample sizes, limited control groups, or different treatment protocols. Therefore, PRP should not be regarded as a proven alternative to standard IVF treatment. If it is recommended, its experimental nature, potential benefits, uncertainties, and additional costs should be clearly assessed during the written informed consent process.
Uncertainties in stem cell-assisted treatments
Stem cell or cellular therapies are being investigated with the aim of restoring ovarian tissue function. At present, there is insufficient high-quality evidence that these approaches reliably increase live birth rates.
When stem cell treatment is recommended, patients should ask about the source of the cells, laboratory procedures, quality control, route of administration, clinical research approval, and long-term follow-up plan. The term “stem cell-assisted” alone does not mean that a treatment is standard, safe, or effective. Applications that are not conducted directly within a clinical research framework require careful decision-making based on written information.
Safety and authorization when assessing low AMH in Turkey
When choosing a center for health tourism in Turkey, selecting organizations that hold a Health Tourism Authorization Certificate issued by the Ministry of Health is a fundamental check to help ensure that services are provided in accordance with regulations. The certificate's validity, the institution's name, and the scope of authorization should be verified through official channels.
An authorized IVF center should be able to evaluate AMH, antral follicle counting, ovarian stimulation, follicular monitoring, egg retrieval, microinjection, and embryo culture within the same overall plan. The experience of Turkish reproductive endocrinology teams with clinical situations such as diminished ovarian reserve, poor response, and repeated failed attempts should be assessed not only through promotional claims, but also through the center's age-specific outcome reports and laboratory procedures.
You can ask whether live birth rates are broken down according to age, number of embryos, and method used. If PRP or stem cell treatment is recommended, the center should also explain how the contribution of the experimental application will be measured separately from the standard IVF outcome.
Scope of a PRP and low AMH IVF plan in Turkey
The planned logistics package may include airport or intra-city VIP transfers, accommodation, interpreter support, and coordination of initial post-procedure care and any medications deemed necessary; the scope, hotel standard, and companion arrangements should be checked in writing. The name of a package does not guarantee the effectiveness of an experimental application or a pregnancy outcome.
The length of stay in Turkey varies depending on whether PRP is performed and on the ovarian stimulation plan. For the initial assessment, ultrasound, hormone tests, previous treatment records, semen analysis, and any necessary infection screening may be reviewed. If the IVF cycle is to be completed during the same trip, approximately two to three weeks may be required from the start of menstruation to egg retrieval; the decision regarding embryo transfer or freezing depends on the clinical findings.
When traveling from abroad, prepare the dates of your AMH and other hormone results, ultrasound reports, previous stimulation protocols, numbers of eggs and embryos collected, fertilization results, and any genetic test reports, with English or Turkish translations. Before traveling for stem cell or PRP treatment, request written information about the procedure's ethics committee, clinical research, and regulatory status.
Comparing the costs of low AMH IVF and PRP in Turkey
In Turkey, the average package cost for standard IVF treatment may range from approximately €2,500–€5,000 at many centers. This range does not always include medications, genetic testing, additional laboratory procedures, or experimental PRP treatment.
| Country | Approximate range for standard IVF | Notes on low AMH and additional procedures |
|---|---|---|
| Turkey | €2,500–€5,000 | Medication, PRP, genetic testing, and additional laboratory fees may be calculated separately. |
| United Kingdom | £7,000–£12,000 | Private center fees may increase with medication, storage, and additional tests. |
| Germany | €4,000–€8,000 | Insurance coverage, age, and treatment conditions may affect the total payment. |
| United States | $15,000–$25,000 | Medication, anesthesia, embryo storage, and genetic testing are often priced separately. |
An additional fee of approximately €500–€1,500 may be quoted for PRP; the amount varies according to the center, application method, and follow-up plan. Since there is no standardized price or proven treatment package for stem cell applications, assess the legal and scientific status of the procedure rather than comparing only the total price.
Low AMH factors that affect the price and treatment plan
- Physician's specialization and experience: Training in reproductive endocrinology and experience with diminished ovarian reserve and poor-response protocols may affect the quality of follicular monitoring and egg retrieval planning. It is important for the center to present its outcomes according to age group and ovarian reserve.
- Technology, methods, and materials: Standard IVF and ICSI, or intracytoplasmic sperm injection, continuous imaging systems for embryo culture, vitrification freezing, and preimplantation genetic testing do not have the same costs. For PRP, the blood-processing system and application protocol should be reviewed; for stem cell treatment, the cell source, laboratory quality controls, and research status should also be examined.
- Clinic location: Clinic, laboratory, accommodation, and transportation costs may differ in Istanbul, Ankara, Izmir, and other cities. When choosing a city, consider not only the price but also whether all procedures are carried out at the same center and whether an emergency communication plan is available.
Three specific questions to ask before coming to Turkey
- When my AMH level, antral follicle count, and age are assessed together, what number of eggs is considered a realistic target for retrieval? The answer provides a more meaningful treatment framework than a single AMH result.
- What clinical evidence, ethics committee decision, and follow-up criteria support the recommended PRP application? Ask in writing how outcomes such as egg number, embryo development, and live birth will be monitored.
- Is the stem cell option a standard treatment or a clinical study, and what is the alternative plan if the procedure is unsuccessful? Do not make a decision until the cell source, risks, additional costs, long-term follow-up, and reimbursement conditions are clear.
You should make the final decision together with a specialist who evaluates your medical history and current test results. Low AMH is an important finding; however, it does not by itself eliminate the possibility of pregnancy, and PRP or stem cell applications should not be presented as a promise of guaranteed success.